Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Jurikova, Lenka
GUARDIAN, NCT06713135: A Study on Safety and Effectiveness of Long-term Treatment With Vamorolone in Boys With Duchenne Muscular Dystrophy	Recruiting	4	80	Europe, RoW	vamorolone 40 mg/mL oral suspension, vamorolone	Santhera Pharmaceuticals	Duchenne Muscular Dystrophy	09/28	09/28
MIS51ON, NCT03992430 / 2018-001762-42: A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD)	Active, not recruiting	3	160	Europe, US, RoW	Eteplirsen, AVI-4658, EXONDYS 51, EXONDYS	Sarepta Therapeutics, Inc., Sarepta Therapeutics, Inc.	Muscular Dystrophy, Duchenne	10/26	10/26
Svobodova, Monika
CALLIPER, NCT05054140 / 2021-000048-23: Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis	Active, not recruiting	2	450	Europe, Canada, US, RoW	IMU-838, Vidofludimus calcium, Placebo matching IMU-838, Placebo Arm	Immunic AG	Multiple Sclerosis	01/25	01/25